Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seprehvir in Recurrent Childhood High Grade Gliomas
NCT02031965Phase 1Terminated
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Dec 2013
- Primary completion
- May 2016
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSV-1716 in high-grade glioma (HGG), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Maximum Tolerated Dose at 56 days, Dose-Limiting Toxicities at 56 days and 2 more. Started Dec 2013; status: terminated.
02
Drugs
HSV-1716
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02031965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031965.